Edward Jay Epstein is the first journalist to have investigated the official accounts of the assassination of John F. Kennedy. He remains the only one to have interviewed all the members of the Warren Commission — the ad hoc group of political heavies impaneled by then-president Lyndon Johnson to lay to rest all questions in the case — save for Chief Justice Earl Warren himself.
Epstein’s book, Inquest, published in 1966, arguably began the modern conspiracy business. The JFK Assassination Diary: My Search for Answers to the Mystery of the Century, his contemporaneous account of his byplay with the commission’s members and staff — and later efforts to see the trees though the conspiracy theories — has just been published in time for next month’s 50th anniversary of the great crime.
Top 5 Medical Companies To Own For 2014: Stemline Therapeutics Inc (STML)
Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline’s StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bul k of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.
SL-401 – An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk
SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancer s, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.
SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.
StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.
StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and follo wing CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.
The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird’s case, the price that had actually opened up as an IPO, even though it’s above its IPO price.
- [By David Zeiler]
3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.
- [By Keith Speights]
Best-performing biotech IPO
Stemline Therapeutics (NASDAQ: STML ) has only traded publicly this year, but what a year it’s been. The stock’s performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.
Top 5 Medical Companies To Own For 2014: Alpha Pro Tech Ltd (APT)
ALPHA PRO TECH, LTD. (Alpha Pro Tech), incorporated on June 15, 1994, is in the business of protecting people, products and environments. The Company also manufactures a line of building supply construction weatherization products through its wholly-owned subsidiary, Alpha ProTech Engineered Products, Inc. Its products are sold under the Alpha Pro Tech brand name, as well as under private label. The Company’s products are grouped into three business segments: the Building Supply segment, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, the Disposable Protective Apparel segment, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products and the Infection Control segment, which consists of face masks and eye shields.
The Building Supply segment consists of a line of construction supp ly weatherization products, namely housewrap and synthetic roof underlayment. This line of products is a natural extension of the Company’s core capabilities: creating products designed to protect people and environments. The housewrap, under the trademark REX, offers a weather resistant barrier and, to the homeowner, years of lower energy consumption. REX Wrap and REX Wrap Plus are woven and coated polypropylene micro perforated weather resistant barriers, and REX Wrap Fortis is an engineered composite made up of a woven fabric, a monolithic breather film and a non-woven sheet, offering a non-perforated membrane.
Disposable Protective Apparel
The Disposable Protective Apparel segment includes many different styles of disposable products, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. The products are manufactured by subcontractors in Asia and, to a much lesser extent, a subcontractor in Mexi co. Certain products are made using materials supplied by th! e Company.
The Infection Control segment includes face masks and eye shields. The Company’s face masks come in a range of filtration efficiencies and styles. The Company’s Positive Facial Locka feature provides a custom fit to the face to prevent blow-by for better protection. The Company’s Magic Arch feature holds the mask away from the nose and mouth, creating a comfortable breathing chamber.
Kimberly Clark, 3M Company, Johnson & Johnson, White Knight/Precept, Cardinal Health, Inc., Medline Industries Inc., VWR International, LLC, Kimberly Clark, 3M Company, Kappler USA, DuPont and Allegiance Health Care.
- [By Cindy Bowser]
Alpha Pro Tech (APT) is a Delaware corporation headquartered in Ontario. APT was our “Company of the Month” feature in August 2000 at $1.31 per share.
Top 5 Medical Companies To Own For 2014: Sunshine Heart Inc (SSH)
Sunshine Heart, Inc., incorporated on August 22, 2002, is an early-stage medical device company focused on developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. The C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. As of December 31, 2011, the Company was in the process of obtaining regulatory approvals necessary to sell its product.
The Company has developed tools to allow the C-Pulse to be implanted through a small pacemaker-like incision between the patient’s ribs and sternum rather than a sternotomy. Patients implanted through its minimally invasive procedure require a hospital stay of four to seven days in connection with impl antation of the C-Pulse System, after which they return home. During the year ended December 31, 2011, the Company completed enrollment and implantation of 20 patients in the North American feasibility phase of its trial. In April 2011, the Food and Drug Administration (FDA) approved an expansion protocol to allow the Company to implant up to 20 additional patients and add two additional centers to its feasibility study.
The Company competes with Thoratec Corporation, HeartWare International Inc., CircuLite, Inc., CardioKinetix, Inc., AbioMed, Inc., Jarvik Heart, Inc., MicroMed Technology, Inc., SynCardia Systems, Inc., Terumo Heart, Inc., WorldHeart Corporation in the United States and Europe, and Berlin Heart GmbH in Europe.
- [By John Udovich]
Small cap heart stocks Sunshine Heart Inc (NASDAQ: SSH), Abiomed, Inc (NASDAQ: ABMD) and AtriCure Inc (NASDAQ: ATRC) each find different ways go to the heart of the problem for cardiac patients and have all been good performers for investors this year. After all and according to statistics collected by the CDC, heart disease is the leading cause of death for both men and women as about 600,000 people die of heart disease in the United States every year – accounting for 1 in every 4 deaths. Moreover, roughly 715,000 Americans have a heart attack every year and ff these, 525,000 are a first heart attack and 190,000 happen to people who have already had one. In other words, there is a big market for the following small cap heart stocks to address:
Top 5 Medical Companies To Own For 2014: Five Prime Therapeutics Inc (FPRX)
Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company’s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.
FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.
FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable diso rders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.
FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor’s surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients’ t umors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.
- [By John Kell and Tess Stynes var popups = dojo.query(“.socialByline .popC”); p]
Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)
- [By Monica Gerson]
Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.
Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Top 5 Medical Companies To Own For 2014: Integra LifeSciences Holdings Corp (IART)
Integra LifeSciences Holdings Corporation (Integra), incorporated on June 19, 1989, is an integrated medical technology company. Integra offers solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. The Company has developed numerous product lines for applications ranging from burn and deep tissue wounds to regeneration of dura mater in the brain and repair of nerve and tendon. It operates in five business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The International segment sells similar products to Europe, Middle East and Africa, and Central/South America, Asia-Pacific and Canada. On April 29, 2013, the Company launched the Integra Compact Cranial Closure System, which provides titanium implants for non-loadbearing (non-facial) operative cranial neurosurgical procedures. On April 30, 2013, it released its Hollywood VI intervertebral body fusion device (I BD) system. In January 2014, Integra LifeSciences Holdings Corp completed the acquisition of DuraSeal product lines from Covidien. In January 2014, Covidien PLC completed the sale of its Confluent Surgical product line to Integra LifeSciences Corporation.
The Company’s U.S. Neurosurgery sales organization sells a full line of products for neurosurgery and neuro critical care. It has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, cerebral spinal fluid (CSF) management devices, tissue ablation equipment, intracranial monitoring equipment and cranial stabilization equipment. The Company sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit (NICU).
Extremity reconstruction includes the repair of soft tissue and the orthopedic reconstruction of bone in the foot, an kle and leg below the knee (Lower Extremity), and the hand, ! wrist, elbow and shoulder (Upper Extremity). Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist arthroplasty, carpel tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes.
Integra’s U.S. Instruments business is a surgical instrument suppliers in the United States. Its portfolio includes over 60,000 instrument patterns and surgical products sold a range of users, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. The Company’s brands include Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract.
U.S. Spine and Oth er
Integra’s U.S. Spine and Other segment offer spinal fusion technologies that surgeons use along the full length of the spine, as well as a range of related orthobiologics. During the year ended December 31, 2012, its Spine business launched multiple new implants into the integrated interbody fusion device market and the deformity market. Its key spinal hardware products include integrated interbody fusion devices, minimally invasive solutions, and deformity correction. It markets and sells a complete line of orthobiologics, including demineralized bone products, collagen ceramic matrices and pure synthetic bone grafting solutions, to neurosurgeons, and spine, orthopedic, trauma, and foot and ankle surgeons. Integra sells its products through specialty distributors focused on its spine and orthopedic surgeon customers, as well as through some direct sales representatives. This segment also includes private-label sales of a set of its regenerative medicine te chnologies. Its customers are other large medical technology! companie! s that sell to end markets primarily in orthopedics and wound care.
The Company competes with Johnson & Johnson, Synthes, Inc., Stryker Corporation, Tornier, Inc., Wright Medical Group, Inc., Zimmer, Inc., Small Bone Innovations, Inc., Medtronic, Inc., Globus Medical Inc., NuVasive, Inc., Orthofix, Alphatec Spine, Inc., B. Braun Medical Inc., CareFusion and Symmetry Medical.
- [By Ben Levisohn]
Shares of Align have surged 24% to $57 at 12:37 p.m. Sirona Dental Systems (SIRO) has risen 0.8% to $69.61, Dentsply International (XRAY) is up 0.1% at $45.44, Integra Lifesciences (IART) has gained 0.4% to $44.23 and Danaher (DHR) has fallen 0.3% to $72.13.
- [By Sean Williams]
What: Shares of Integra LifeSciences (NASDAQ: IART ) , a manufacturer of surgical instruments and medical implants, fell as much as 13% after the company announced a voluntary recall of certain products at its Anyasco manufacturing facility in Puerto Rico.
- [By Keith Speights]
Medical instrument maker Integra LifeSciences (NASDAQ: IART ) shares dropped 11% this week. The stock’s fall stemmed from a product recall announced on Wednesday.
- [By Seth Jayson]
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven’t materialized. Is the current inventory situation at Integra LifeSciences Holdings (Nasdaq: IART ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Integra LifeSciences Holdings doing by this quick checkup? At first glance, OK, it seems. Trailing-12-month revenue increased 4.5%, and inventory increased 4.1%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue expanded 0.2%, and inventory increased 4.1%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 8.3%, and inventory grew 4.5%.